(firstQuint)A Safety Study of LY2811376 Single Doses in Healthy Subjects.

 This is a Phase 1 study with 2 parts, both in healthy subjects.

 Part 1 is a subject- and investigator-blind, placebo-controlled, randomized, 3 period, crossover study.

 Part 1 will assess the safety and tolerability of LY2811376 single doses, how the body handles the drug, and the drug's effect on the body.

 Part 2 is a subject- and investigator-blind, placebo-controlled, randomized study to assess the safety and tolerability of a LY2811376 single dose, how the body handles the drug, and the drug's effect on the body including in cerebrospinal fluid.

.

 A Safety Study of LY2811376 Single Doses in Healthy Subjects@highlight

This is a Phase 1 study in healthy subjects to evaluate the safety and tolerability of LY2811376 single doses, how the body handles the drug, and the drug's effect on the body.

